Skip to main content
SpringerLink
Log in
Book cover

ADS/ADHS Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung pp 25–29Cite as

Fortschritte in der Pharmakotherapie

  • Conference paper

  • 619 Accesses

Zusammenfassung

Neben der Beratung und den psychosozialen Interventionen nimmt die Pharmakotherapie im multimodalen Therapiekonzept von ADS/ADHS eine zentrale Rolle ein. Derzeit gelten Stimulanzien wie Methylphenidat als Mittel der Wahl. Neue medikamentöse Optionen wie Atomoxetin versprechen zukünftig möglicherweise Fortschritte in der Behandlung von ADS/ADHS.

This is a preview of subscription content, log in via an institution.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abikoff H, Hechtman L (1996) in Jensen PS, Hibbs ED (eds.) Psychosocial treatment for child and adolescent disorders: empirically based approaches, 341–69, American Psychological Association, Washington DC

    Chapter  Google Scholar 

  2. Wilens TE et al. (2003) Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 111(1): 179–8

    Article  PubMed  Google Scholar 

  3. Zametkin AJ, Ernst M (1999) Problems in the management of attention-deficit-hyperactivity disorder. N Engl J Med 340(1): 40–6

    Article  PubMed  CAS  Google Scholar 

  4. Barkley RA (1998) Attention-Deficit/Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. Guilford Press, New York; Barkley RA et al. (1996) Psychological adjustment and adaptive impariments in young adults with ADHD. Journal of Attention Disorders 1: 41–54; Cunningham CE et al. (1985) A developmental dose-response analysis of the effects of methylphenidate on the peer interactions of attention deficit disordered boys. J Child Psychol Psychiatry 26(6): 955–71

    Google Scholar 

  5. Michelson D et al. (2002) Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159(11): 1896–901

    Article  PubMed  Google Scholar 

  6. Prince JB et al. (2000) A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 10(3): 193–204

    Article  PubMed  CAS  Google Scholar 

  7. Wilens TE et al. (2001) A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 158(2): 282–8

    Article  PubMed  CAS  Google Scholar 

  8. Hunt RD et al. (1985) Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial. J Am Acad Child Psychiatry 24(5): 617–29

    Article  PubMed  CAS  Google Scholar 

  9. Hunt RD et al. (1986) The therapeutic effect of Clonidine in attention deficit disorder with hyperactivity: a comparison with placebo and methylphenidate. Psychopharmacol Bull 22(1): 229–36

    PubMed  CAS  Google Scholar 

  10. Kurlan R et al. (2002) Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 58(4): 527–36

    Google Scholar 

  11. Michelson D et al. (2001) Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108(5): E83

    Article  PubMed  CAS  Google Scholar 

  12. Kratochvil CJ et al. (2002) Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 41 (7): 776–84

    Article  PubMed  Google Scholar 

  13. Spencer T et al. (1998) Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 155(5): 693–5

    PubMed  CAS  Google Scholar 

  14. Wilens TE et al. (1999) A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry 156(12): 1931–7

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Boston, USA

    Timothy E. Wilens

  2. Bad Homburg, Hamburg, Deutschland

    Ralf W. Dittmann

Authors
  1. Timothy E. Wilens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ralf W. Dittmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Abteilung für Kinder- und Jugendpsychiatrie, Universitätsklinikums Hamburg Eppendorf, Martinistraße 52, 20246, Hamburg, Deutschland

    Michael Schulte-Markwort (Stellvertretender Direktor) (Stellvertretender Direktor)

  2. LV Hamburg, Tangstedter Landstraße 77, 22415, Hamburg, Deutschland

    Michael Zinke (Vorsitzender des Berufsverbandes der Kinder- und Jugendärzte) (Vorsitzender des Berufsverbandes der Kinder- und Jugendärzte)

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag Berlin Heidelberg New York

About this paper

Cite this paper

Wilens, T.E., Dittmann, R.W. (2003). Fortschritte in der Pharmakotherapie. In: Schulte-Markwort, M., Zinke, M. (eds) ADS/ADHS Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-92473-6_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-92473-6_7

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-00140-9

  • Online ISBN: 978-3-642-92473-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation